CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for treating HER2-positive breast and gastric cancers. Shares of Aurobindo Pharma Ltd ended at ₹1,157.75, up by ₹25.25, or 2.23%, on the BSE.
